The ALS therapy ATH-1105 entered the brain and spinal cord at dose-proportional levels in healthy volunteers, and had a good ...

Neurizon Therapeutics has reported positive topline results from an open-label extension (OLE) study of its lead candidate ...

ROME, AUG 19 - An Italo-US team of scientists have made a breakthrough in the early diagnosis of amyotrophic lateral sclerosis (ALS), also known as Motor Neuron Disease or Lou Gehrig's Disease, ...

By analyzing millions of messenger RNA molecules (mRNA) during the course of ALS, researchers at Stockholm University, in ...

Yet another biotech is facing a delay from the FDA as the agency reels from intense staffing cuts. | Yet another biotech is ...

A new brain-computer interface can decode a person's inner speech, which could help people with paralysis communicate.

The U.S. Food and Drug Administration has approved the ketamine product, KETARx, for use in surgical pain management.

A new brain-computer interface technology can decode a user’s inner monologue, an advance that scientists say can help ...

Raffaella Uccelli, Alessandra Binazzi, Pierluigi Altavista, Stefano Belli, Pietro Comba, Marina Mastrantonio, Nicola Vanacore, Geographic distribution of amyotrophic lateral sclerosis through motor ...

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease predominantly affecting upper and lower motor neurons. Here, the authors outline previous and current efforts to characterize ...

• Key Amyotrophic Lateral Sclerosis Pipeline Therapies: ION363, FB418, SRK-015, RNS60, QRL-201, SAR443820, MN-166, VM202, VRG-50635, Zilucoplan, and others.